GlycoEra adds Dr. Santiago Arroyo to its Board as Independent Director

– SWITZERLAND, Zurich / USA, MA –  GlycoEra AG, a biotechnology company building a high-value pipeline of medicines based on deep expertise in protein degradation of circulating and membrane targets, today announced the appointment of Dr. Santiago Arroyo (MD) to its Board as an Independent Director.

“Santiago will be a tremendous asset to our company as we continue to build GlycoEra and advance our mission of developing life-changing therapies for patients. We look forward to working closely with him and benefiting from his strategic insights, deep leadership, and operational expertise,” said Board Chairman, Georges Gemayel.

About Dr. Santiago Arroyo

Dr. Santiago Arroyo is a tenured pharmaceutical executive who has deep expertise in strategy and leading the clinical development of therapeutics across multiple disease areas. He is currently CDO of Bicycle Therapeutics. Before joining Bicycle, Dr. Arroyo held a CMO position at Momenta Pharmaceuticals, leading the company’s clinical development programs until Momenta’s acquisition by Johnson & Johnson. Previously, he was CMO of Boston Pharmaceuticals. Before that, he held multiple senior clinical development leadership roles at leading pharmaceutical companies including Pfizer, Inc., Bristol-Myers Squibb, Eisai Global Clinical Development, and Schwarz Biosciences.

“I am excited to join the Board of Directors of GlycoEra and help develop a portfolio of transformative therapeutics based on the innovative platform for degrading extracellular protein targets. I look forward to working together with the highly experienced Board and leadership team to build GlycoEra into a leading protein degradation company” said Dr. Santiago Arroyo.

Dr. Arroyo was an Instructor at the Johns Hopkins Medical School, Associate Professor at the Medical College of Wisconsin, and Senior Specialist at the Hospital Clinic of Barcelona. He earned a Ph.D. from the Universidad de Barcelona and an M.D. from the Universidad Autonóma de Madrid. Dr. Arroyo is also a non-executive director of Lundbeck.

About GlycoEra AG

GlycoEra AG is a biotechnology company building a high-value pipeline of medicines based on deep expertise in glycobiology and protein degradation. GlycoEra’s innovative CustomGlycan platform enables the design, engineering, and development of novel biologics for a broad range of indications. GlycoEra is advancing a range of assets toward human clinical studies. The company raised more than $49 million (CHF 45 million) in a 2021 Series A financing round co-led by 5 AM Ventures, Sofinnova Partners, and Roche Venture fund. GlycoEra is based in Wädenswil, Switzerland, and Newton, Massachusetts USA.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.